Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology

0503882 - MBÚ 2020 RIV GB eng J - Článek v odborném periodiku
Laaf, D. - Bojarová, Pavla - Elling, L. - Křen, Vladimír
Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology.
Trends in Biotechnology. Roč. 37, č. 4 (2019), s. 402-415. ISSN 0167-7799. E-ISSN 1879-3096
Grant CEP: GA ČR(CZ) GA18-01163S; GA MŠMT(CZ) LTC17005; GA MŠMT(CZ) LTC18038; GA MŠMT(CZ) LTC18041
Institucionální podpora: RVO:61388971
Klíčová slova: chemoenzymatic synthesis * glycodendrimers * glycoproteins
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 14.343, rok: 2019
Způsob publikování: Omezený přístup
https://www.sciencedirect.com/science/article/pii/S0167779918302646?via%3Dihub

Cellular communication events are mediated by interactions between cell-surface sugars and lectins, which are carbohydrate-binding proteins. Galectins are beta-galactosyl-binding lectins that bridge molecules by their sugar moieties, forming a signaling and adhesion network. Severe changes in glycosylation and galectin expression accompany major processes in oncogenesis, cardiovascular disorders, and other pathologies, making galectins attractive therapeutic targets. Here we discuss advanced strategies of chemo-enzymatic carbohydrate synthesis for creating lead glycomimetics and (neo-) glycoconjugates for galectin-1 and -3 targeting in biomedicine and biotechnology. We will describe the challenges and bottlenecks on the route into biomedical and biotechnological practice and present the first clinical candidates. The coming era will see an exciting translation of selective well-defined high-affinity galectin ligands from bench to bedside.
Trvalý link: http://hdl.handle.net/11104/0295654